辰欣药业及控股子公司拟使用闲置自有资金进行委托理财及证券投资

Group 1 - The core point of the article is that Chenxin Pharmaceutical (603367.SH) announced plans to use idle self-owned funds for entrusted wealth management and securities investment, with a total amount not exceeding RMB 2.9 billion [1] Group 2 - The entrusted wealth management amount will not exceed RMB 2.3 billion [1] - The securities investment amount will not exceed RMB 600 million [1] - The fund usage period is set for 12 months from the date of the board's approval of this proposal [1]